Clinical Trials Browser

Terminated × palbociclib × Clear all

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT03535506 2025-09-26

WI223281

Phase 2 Terminated

17 enrolled 9 charts

Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast Neoplasms

NCT04060862 2024-11-08

IPATunity150

Phase 1 Terminated

20 enrolled 11 charts

Breast Neoplasms

NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Phase 2 Terminated

10 enrolled 15 charts

Recurrence, Sarcoma, Sarcoma, Ewing

NCT03322215 2024-03-08

PASIPHAE

Phase 2 Terminated

Breast Cancer Metastatic

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 1/2 Terminated

HER2-positive Breast Cancer

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03386929 2023-12-18

SPRING

Phase 1/2 Terminated

15 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

Neoplasms

NCT03128619 2022-09-26

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase 1 Terminated

Breast Neoplasms

NCT03220178 2022-01-06

PRECYCLE

Phase 4 Terminated

Breast Neoplasms, Neoplasm Metastasis

NCT02907918 2021-09-29

PALTAN

Phase 2 Terminated

26 enrolled 8 charts

Breast Neoplasms

NCT01823835 2021-06-18

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

152 enrolled 42 charts

Breast Neoplasms

NCT02349633 2021-06-10

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Phase 1/2 Terminated

65 enrolled 61 charts

Carcinoma, Non-Small-Cell Lung

NCT02255461 2021-03-02

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Phase 1 Terminated

35 enrolled 28 charts

Astrocytoma, Glioblastoma, Medulloblastoma, Oligodendroglioma, Choroid Plexus Neoplasms, Neoplasms, Neuroepithelial

NCT03515200 2020-09-01

Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1 Terminated

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02774681 2020-04-14

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Phase 2 Terminated

12 enrolled 11 charts

Breast Neoplasms

NCT01111188 2019-06-27

Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

Phase 1 Terminated

Lymphoma, Mantle-Cell